Home » FDA » Page 23

Tag Archives: FDA

The Futile Quest of Proofing a Negative in the Presence of Overwhelming Absence of Harm

Posted on by — No Comments ↓

The cartilage damage caused by fluoroquinolones in juvenile beagle dogs is not subtle:  blister formation and erosions occur in a dose-dependent fashion resulting in reversible cartilage damage.  These lesions can be seen not just histologically but even macroscopically.  The animals are unable to walk as weight-bearing joints are predominantly affected.  Continue reading The Futile Quest of Proofing a Negative in the Presence of Overwhelming Absence of Harm→

Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study

Posted on by — No Comments ↓

Solomkin et al. conclude that the efficacy and safety of eravacycline compares favorably to the control drug, ertapenem.[1]  This top-level assessment is made with the usual caveats (insufficient statistical power, small sample size), but a few points deserve comment. Eravacycline is a fluorocycline; as a tetracycline derivative it follows into Continue reading Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study→

The Rapid Rise of Sulfonamide Diversity

Posted on by — No Comments ↓

Shortly after Domagk and Hörlein announced their discovery of the antibacterial properties of the dye sulfamidochrysoidine (Prontosil) in 1935, numerous chemical companies set out to modify the chemical structure.  They soon recognized the sulfa component as the true antibacterial and produced an incredible number of derivatives (more than 5000 different compounds!!) by 1945.[1, Continue reading The Rapid Rise of Sulfonamide Diversity→